PepGen(PEPG) - 2024 Q1 - Quarterly Results

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights potentially support a future accelerated approval pathway, subject to regulatory authority feedback. – CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net proceeds of $86.3 million from common stock offerings extending cash runway into 2026 – BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- PepGen In ...